Destiny Pharma plc (LON:DEST – Get Free Report) shot up 24.3% during trading on Monday following insider buying activity. The stock traded as high as GBX 2.98 ($0.04) and last traded at GBX 2.98 ($0.04). 191,948 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 604,098 shares. The stock had previously closed at GBX 2.40 ($0.03).
Specifically, insider Nigel Rudd acquired 1,240,000 shares of the stock in a transaction dated Friday, August 2nd. The stock was acquired at an average cost of GBX 0.25 ($0.00) per share, with a total value of £3,100 ($3,961.66). 24.65% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Separately, Shore Capital restated a “house stock” rating on shares of Destiny Pharma in a report on Monday, July 15th.
Destiny Pharma Stock Performance
The company has a 50 day simple moving average of GBX 8.88 and a two-hundred day simple moving average of GBX 23.57. The firm has a market cap of £3.38 million, a PE ratio of -64.08 and a beta of 0.31.
About Destiny Pharma
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.
Read More
- Five stocks we like better than Destiny Pharma
- Overbought Stocks Explained: Should You Trade Them?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- What is a Death Cross in Stocks?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- There Are Different Types of Stock To Invest In
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.